Effects of acute CDP-choline treatment on resting state brain oscillations in healthy volunteers

Neuroscience Letters

Volumn 591, Issue , 2015, Pages 121-125

  Knott, Verner ^a   Salle, Sara de la ^a   Smith, Dylan ^a   Choueiry, Joelle ^a   Impey, Danielle ^a   Smith, Meaghan ^a   Beaudry, Elise ^a   Saghir, Salman ^a   Ilivitsky, Vadim ^a   Labelle, Alain ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Choline; Cognition; Cytidine 5' diphosphocholine; Nicotinic receptors; Oscillations

Indexed keywords

CHOLINE; CITICOLINE; PLACEBO; NICOTINIC AGENT;

ADULT; ALPHA RHYTHM; ARTICLE; BETA RHYTHM; CONTROLLED STUDY; CROSSOVER PROCEDURE; DELTA RHYTHM; DOSE RESPONSE; ELECTROENCEPHALOGRAM; ELECTROENCEPHALOGRAPHY; GAMMA RHYTHM; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; NORMAL HUMAN; OSCILLATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTING STATE NETWORK; SINGLE DRUG DOSE; THETA RHYTHM; YOUNG ADULT; BRAIN; BRAIN MAPPING; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; PHYSIOLOGY; REFERENCE VALUE;

BRAIN; BRAIN MAPPING; CROSS-OVER STUDIES; CYTIDINE DIPHOSPHATE CHOLINE; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; HUMANS; MALE; NICOTINIC AGONISTS; REFERENCE VALUES; YOUNG ADULT;

EID: 84923253580     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2015.02.032     Document Type: Article

References (60)

1. Weiss G. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sci. 1995, 56:637-660.
2. Secades J., Lorenzo J. Citicoline: pharmacological and clinical review , 2006 update. Methods Find. Exp. Clin. Pharmacol. 2006, 1-56. (Suppl B).
3. Saver J. Citicoline: update on a premixing and widely available agent for neuroprotection and neurorepair. Rev. Neurol. Dis. 2008, 5:167-177.
4. Levin E. Complex relationships of nicotinic receptor actions and cognitive functions. Biochem. Pharmacol. 2013, 86:1145-1152.
5. Singh A., Potter A., Newhouse P. Nicotinic acetylcholine receptor system and neuropsychiatric disorders. J. Drugs 2004, 7:1096-2103.
6. Babb S., Appelmans K., Renshaw P., Wurtman R., Cohen B. Differential effect of CDP-choline on brain systolic choline levels in younger and older subjects as measured by proton magnetic resonance spectroscopy. Psychopharmacology 1996, 127:88-94.
7. Cohen B., Renshaw P., Stoll A., Wurtman R., Yurgelun-Todd D., Babb S. Decreased brain choline uptake in older adults. JAMA 1995, 274:902-907.
8. Millington W., Wurtman R. Choline administration elevates brain phosphorylcholine concentrations. J. Neurochem. 1982, 38:1748-1752.
9. Michel C., Murray M. Towards the utilization of EEG as a brain imaging tool. Neuroimage 2012, 61:371-385.
10. Leiser J., Dunlop M. Aligning strategies for using EEG as a surrogate biomarker: a review of preclinical and clinical research. Biochem. Pharmacol. 2011, 81:1408-1421.
11. Saletu B., Anderer P., Saletu-Zyhlarz G., Arndol O., Pascual-Marqui R. Classification and evaluation of the pharmacodynamics of psychotropic drugs by single-lead pharmaco-EEG, EEG mapping and tomography (LORETA). Methods Find. Exp. Clin. Pharmacol. 2002, 24:97-120.
12. Knott V. Quantitative EEG methods and measures in human psychopharmacological research. Hum. Psychopharmacol. 2000, 15:479-498.
13. Knott V. Neuroelectric approach to the assessment of psychoactivity in comparative substance use. Addiction Controversies 1990, 66-89. Harwood Academic Pub., Switzerland. D. Warburton (Ed.).
14. Knott V., Venables P. EEG alpha correlates of non-smokers: smoking and smoking deprivation. Psychophysiology 1977, 14:150-156.
15. Knott V. Electroencephalographic characterization of cigarette smoking behaviour. Alcohol 2001, 24:95-97.
16. Alkondon M., Albuquerque E. Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons I. Pharmacological and functional evidence for distinct structural subtypes. J. Pharmacol. Exp. Ther. 1993, 266:1455-1473.
17. Zhang Z., Vijayaraghavan S., Berg D. Neuronal acetylcholine receptors that bind α-bungarotoxin with high affinity functions as ligand sated ion channels. Neuron 1994, 12:167-177.
18. Williams J., Gibbon M., First M., Spitzer R., Davies M., Borus J., Howes M., Kane J., Pope H., Rounsaville B. The structured clinical interview for the DSM-III-R (SCIDII). Multisite test-retest reliability. Arch. Gen. Psychiatry 1992, 49:630-636.
19. Maxwell M. Family interview for genetic studies [FIGS]: manual for FIGS. Clinical Neurogenetics Branch, Intramural Research Program 1992, National Institute of Mental Health, Bethesda.
20. Cropsey K., Eldridge G., Weiver M., Villalobos G., Stitzer M. Expired carbon monoxide levels in self-reported smokers and non-smokers in prison. Nicotine Tob. Res. 2006, 8:633-659.
21. Wurtman R., Regun M., Ulus J., Yu L. Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem. Pharmacol. 2000, 60:989-992.
22. Chatrian G., Lettich E., Nelson P. Ten percent electrode system for topographic studies of spontaneous and evoked EEG activity. Am. J. EEG Technol. 1985, 25:83-92.
23. Winterer G., Ziller M., Dorn H., Frick K., Mulert C., Wuebben Y., Herrmann W.M., Coppola R. Schizophrenia: reduced signal-to-noise ratio and impaired phase-locking during information processing. Clin. Neurophysiol. 2000, 111:837-849.
24. Knott V. Dynamic EEG changes during cigarette smoking. Neuropsychobiology 1988, 19:54-60.
25. Lindgren M., Molander L., Vesbnan C., Lunell E., Rosen I. Electroencephalographic effects of intravenous nicotine - a dose response study. Psychopharmacology 1999, 145:342-350.
26. Pickworth W., Herning R., Henningfield J. Electroencephalographic effects of nicotine chewing gum in humans. Pharmcol. Biochem. Behav. 1986, 25:879-882.
27. Knott V., Bossman M., Mahoney C., Ilivitsky V., Court K. Transdermal nicotine: single dose effects on mood EEG, performance, and event-related potentials. Pharmacol. Biochem. Behav. 1999, 63:253-261.
28. Teter C., Asfaw B., Lisong N., Lutz M., Domino E., Guthrie S. Comparative effects of smoking and nasal nicotine. Eur. J. Pharmacol. 2002, 58:309-314.
29. Ashare R., Falcone M., Lerman S. Cognitive function during nicotine withdrawal: implications for nicotine dependence treatment. Neuropharmacology 2014, 76:581-591.
30. Beaver J., Long C., Cole D., Durran M., Bannon L., Michara R., Matthews P. The effects of nicotine replacement on cognitive brain activity during smoking withdrawal: studies with simultaneous fMRI/EEG. Neuropsychopharmacology 2011, 36:1792-1800.
31. Cole D., Beckmann C., Long C., Matthews P., Durran M., Beaver J. Nicotine replacement in abstinent smokers improves cognitive withdrawal symptoms with modulation of resting brain network dynamics. Neuroimage 2010, 52:590-599.
32. Knott V., McIntosh J., Millar A., Fisher D., Villeneuve C., Ilivitsky V., Horn E. Nicotine and smoker status moderate brain electric and mood activation induced by ketamine: an N-methyl-d-aspartate (NMDA) receptor antagonist. Pharmacol. Biochem. Behav. 2006, 85:228-242.
33. Fisher D., Jaworska N., Daniels R., Knobelsdorf A., Knott V. Effects of acute nicotine administration on resting EEG in nonsmokers. Exp. Clin. Psychopharmacol. 2012, 20:71-75.
34. Foulds J., McSoreley K., Sneddon J., Feyerabend C., Jarvis M., Russell M. Effects of subcutaneous nicotine injections on EEG alpha frequency in non-smokers. A placebo-controlled pilot study. Psychopharmacology 1994, 115:163-166.
35. Rodriguez J., Kallenbach U., Singer W., Munk M. Short- and long-term effects of cholinergic modulation on gamma oscillations and response synchronization in the visual cortex. J. Neurosci. 2004, 24:10369-10378.
36. Albuquerque E., Peteira E., Kondon M., Rogers S. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol. Rev. 2009, 89:73-120.
37. Dani J., Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Ann. Rev. Pharmacol. Toxicol. 2007, 47:699-729.
38. Mansvelder H., McGhee D. Cellular and synaptic mechanisms of nicotine addiction. J. Neurobiol. 2003, 53:606-617.
39. Wooltorton J., Pidoplichka V., Brosde R., Dani J. Differential desensitization and distribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas. J. Neurosci. 2003, 23:3176-3185.
40. Alkondon M., Pereira E., Cortes W., Maelicke A., Albuquerque E. Choline is a selective agonist of alpha 7 nicotinic acetylcholine receptors in the rat brain neurons. Eur. J. Neurosci. 1997, 9:2734-2742.
41. Albuquerque E., Pereira E., Draga M., Alkondon M. Contribution of nicotinic receptors to the function of synapses in the central nervous system: the action of choline as a selective agonist of alpha 7 receptors. J. Physiol. Paris 1998, 92:309-316.
42. Fayuk D., Yakel J. Regulation of nicotinic acetylcholine receptor channel function by acetylcholinesterase inhibitors in rat hippocampal CA1 interneurons. Mol. Pharmacol. 2004, 66:658-666.
43. Dunbar G., Boeijinga P., Demazieres A., Cisterni C., Kuchibbatla R., Wesnes K., Luthringer R. Effects of TC-1734 (AZD3480) a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology 2007, 191:919-929.
44. Dunbar G., Kochibbatla R. Cognitive enhancement in man with ispronicline: a nicotinic partial agonist. J. Mol. Neurosci. 2006, 30:169-172.
45. Perugini M., Mahoney C., Ilivitsky V., Young S., Knott V. Effects of tryptophan depletion on acute smoking abstinence symptoms and the acute smoking response. Pharmacol. Biochem. Behav. 2003, 74:513-522.
46. Knott V., Raegele M., Fisher D., Robertson N., Millar A., McIntosh J., Ilivitsky V. Clonidine pre-treatment fails to block acute smoking-induced EEG arousal/mood in cigarette smokers. Pharmacol. Biochem. Behav. 2005, 80:161-171.
47. Knott V., Harr A., Ilivitsky V., Mahoney C. The cholinergic basis of the smoking-induced EEG activation profile. Neuropsychobiology 1998, 38:97-107.
48. Walker D., Mahoney C., Ilivitsky V., Knott V. Effects of haloperidol pretreatment on the smoking-induced EEG/mood activation response profile. Neuropsychobiology 2001, 43:102-112.
49. Knott V., Fisher D. Naltexone alteration of the nicotine-induced EEG and mood activation response in tobacco-deprived cigarette smokers. Exp. Clin. Psychopharmacol. 2007, 15:368-381.
50. Conantt R., Schauss A. Therapeutic applications of citicoline for stroke and cognitive dysfunction in the elderly: a review of the literature. Altern. Med. Rev. 2004, 9:17-31.
51. Yang Y., Paspalas C., Jin L., Picciotto M., Arnsten A., Wong M. Nicotinic α7 receptors enhance NMDA cognitive circuits in dorsolateral prefrontal cortex. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:12678-12683.
52. Ilcol Y., Cansev M., Sertac M., Ilmaz Y., Hamurtekin E., Ulus J. Peripheral administration of CDP-choline and its cholinergic metabolites increases serum insulin: muscarinic and nicotinic acetylcholine receptors are both involved in their actions. Neurosci. Lett. 2008, 43:71-76.
53. Gallai V., Mazzotta G., Firenze C., Montesin S., Del Gatto Fr. Study of the P300 and cerebral maps in subjects with multi-infarct dementia treated with cytidine. Pharmacology 1991, 103:1-5.
54. Lopes da Silva F. EEG and MEG: relevance to neuroscience. Neuron 2013, 80:1112-1128.
55. Wang X.-J. Neurophysiological and computational principles of cortical rhythms. Physiol. Rev. 2010, 90:1195-1268.
56. Ettrur A., Mikkelsen J., Lehel S., Madsen J., Nielsen E., Painer M., Timmermann D., Peters D., Knudson G. 11C-NS14492 as a novel PET radioligand for imaging cerebral alpha7 nicotinic acetylcholine receptors: in vivo evaluation and drug occupancy measures. J. Nucl. Med. 2011, 52:1449-1456.
57. Uhlhaas P., Pipa G., Lima B., Melloni L., Neuenschwander S., Nikolic D., Singer W. Neural synchrony in cortical networks: history, concept and current status. Front. Integr. Neurosci. 2009, 3:17.
58. Uhlhaas P., Singer W. Abnormal synchrony and oscillations in neuropsychiatric disorders. Network Approaches to Disease of the Brain 2014, 81-99. Bentham Science Pub., Sharjah, U.A.E. M. Bianchi, V. Caviness, S. Cash (Eds.).
59. E. Basar, B. Guntekin, Review of delta, theta, alpha, beta, and gamma response oscillations in neuropsychiatric disorders. In: Applications of Brain Oscillations in Neuropsychiatric Disorders, E., Basar, C. Basar-Eroglu, A., Ozerdem, P., Rossini, G. Yener (Eds.), Supplement to Clin. Neurophysiol., 62 (2013) 303-341.
60. Buzsaki G., Watson B. Brain rhythms and neural syntax: Implications for efficient coding of cognitive content and neuropsychiatric disease. Dialog. Clin. Neurosci. 2012, 14:345-367.